ArticleFrontiers in immunology2022

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.

James J Harding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.